IL12B and inflammatory bowel disease: For example, our finding that genetic predisposition to higher plasma levels of IL-12B (a subunit of IL-12) was associated with increased risk of IBD is consistent with the therapeutic benefit of ustekinumab (a monoclonal antibody targeting the p40 subunit common to IL-12 and IL-23) in IBD (Supplementary Table 15).